(Report ID: 156066) Drug interactions analysis of: Atorvastatin Calcium, Ramipril, Metolazone, Allopurinol, Furosemide, Carvedilol, Valsartan, Sutent, Albumin (human)Many drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 20, 2008, eHealthMe analyzes 10,180,594 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 20, 2008: 2 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 156066 | May, 7, 2006 | 70 | Male |
List of drugs the patient takes:
| Drug |
Atorvastatin Calcium |
Ramipril |
Metolazone |
Allopurinol |
Furosemide |
Carvedilol |
Valsartan |
Sutent |
Albumin (human) |
List of drug interactions, adverse side effects / events the patient has:
| Name |
Blood Creatine Increased |
Blood Urea Increased |
Culture Wound Positive |
Injection Site Phlebitis |
Pyrexia |
Sepsis |
Staphylococcal Infection |
Nephropathy Toxic |
Results from eHealthMe: 2 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Blood Creatine Increased | 1 (50.00%) |
Blood Urea Increased | 2 (100.00%) |
Culture Wound Positive | 2 (100.00%) |
Injection Site Phlebitis | 2 (100.00%) |
Pyrexia | 2 (100.00%) |
Sepsis | 2 (100.00%) |
Staphylococcal Infection | 2 (100.00%) |
Nephropathy Toxic | 1 (50.00%) |
2) Top drug interactions, adverse side effects reported for the past 12 months:
3) Top co-used drugs drugs reported for the past 12 months:
4) Top drug interactions, adverse side effects reported of all time:Death: 0 Cancer: 0
| Name | Count (% of total reports) |
1 | Sepsis | 2 (100.00%) |
2 | Staphylococcal Infection | 2 (100.00%) |
3 | Injection Site Phlebitis | 2 (100.00%) |
4 | Pyrexia | 2 (100.00%) |
5 | Culture Wound Positive | 2 (100.00%) |
6 | Blood Urea Increased | 2 (100.00%) |
7 | Blood Creatinine Increased | 1 (50.00%) |
8 | Nephropathy Toxic | 1 (50.00%) |
9 | Blood Creatine Increased | 1 (50.00%) |
5) Top co-used drugs drugs reported of all time:
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
Xanax (Pharmacia And Upjohn) - 0.5MG for Stress And Anxiety (Nov, 20, 2008)
|
Carisoprodol (Watson Labs) - 350MG for Pain - Back (Nov, 20, 2008)
|
Side effects comparison of Zoloft (Pfizer) - EQ 200MG BASE (Nov, 20, 2008)
|
Lomotil for Diarrhea (Nov, 20, 2008)
|
Side effects comparison of Nicotine Polacrilex (Perrigo R And D)... (Nov, 20, 2008)
|
Calcium Carbonate, Famotidine And Mag... for GERD (Nov, 20, 2008)
|
Neurontin (Parke Davis) - 600MG for Parasthesia (Nov, 20, 2008)
|
Diovan Hct (Novartis) - 12.5MG;80MG for Blood Pressure - High (Nov, 20, 2008)
|
Nexium for GERD (Nov, 20, 2008)
|
Avastin for Non Small Cell Lung Cancer (Nov, 20, 2008)
|
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|